Skip to main content
OPHLY logo

Ono Pharmaceutical Co., Ltd. (OPHLY) Stock Price & Analysis

Ono Pharmaceutical Co., Ltd. (OPHLY) — price $5.11 (-1.16%), as of the Nov 19, 2026 trading session; market cap $7.21B. Expected results Feb 1, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$5.11 −$0.06 (-1.16%) Market Cap $7.21B

Ono Pharmaceutical Co., Ltd. · OPHLY · Healthcare · Drug Manufacturers - General

Ono Pharmaceutical Co., Ltd., along with its subsidiaries, operates globally, engaging in the research, development, procurement, and commercialization of pharmaceutical products and diagnostic reagents.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • GRFS · Grifols, S.A. · 60 /100
  • OGN · Organon & Co. · 37 /100
  • BIIB · Biogen Inc. · 37 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$5.11
Change on the day-1.16%
52-week range$4.22–$5.75
Market capitalisation$7.21B—
Price / earnings (trailing)15.69
Shares traded on the day24.7K
Beta (volatility vs the S&P 500)0.14
Dividends per share (last 12 months)$0.14
Dividend yield (last 12 months)2.75%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $3.95, high $5.63, latest $5.11. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $5.63 $3.95 high $5.63 Feb 2, 2026 · Earnings results · reported above the recorded estimate · close $4.911May 8, 2026 · Earnings results · reported below the recorded estimate · close $5.232Jul 31, 2026 · Earnings results · reported above the recorded estimate · close $5.033Oct 29, 2026 · Earnings results · reported above the recorded estimate · close $4.714 Oct 17, 2025 Nov 19, 2026 · $5.11 $3.95Oct 17, 2025$3.99Oct 31, 2025$4.37Nov 14, 2025$4.63Nov 28, 2025$4.59Dec 12, 2025$4.60Dec 26, 2025$4.76Jan 9, 2026$4.80Jan 23, 2026$5.28Feb 6, 2026$5.56Feb 20, 2026$5.25Mar 6, 2026$4.84Mar 20, 2026$5.29Apr 2, 2026$5.06Apr 17, 2026$4.86May 1, 2026$5.26May 15, 2026$4.93May 29, 2026$4.70Jun 12, 2026$4.88Jun 26, 2026$4.98Jul 10, 2026$4.93Jul 24, 2026$5.00Aug 7, 2026$5.11Aug 21, 2026$5.17Sep 4, 2026$5.08Sep 18, 2026$4.80Oct 2, 2026$4.98Oct 16, 2026$4.71Oct 30, 2026$5.16Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleDec 1, 2026, Dividend payment date; Feb 1, 2027, Next results due. Spacing is order only and carries no duration.Nov 19, 20261Dec 1, 20262Feb 1, 2027
  1. Dividend payment dateCompany record
  2. Next results dueProvider estimate
How to read these dates

Events are in date order; the spacing is not a duration scale. Estimated dates can change.

What to watch next

Other perspectives

Council score for Ono Pharmaceutical Co. (OPHLY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Moderate
Revenue Growth Moderate
Debt/Equity Moderate
ROE Neutral
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Ono Pharmaceutical Co. (OPHLY), and what does it report?

Short answer

Ono Pharmaceutical Co., Ltd., along with its subsidiaries, operates globally, engaging in the research, development, procurement, and commercialization of pharmaceutical products and diagnostic reagents. Healthcare / Drug Manufacturers General Headquarters: 8-2, Kyutaromachi 1-chome, Osaka, OS, 541-8564, JP. It employs 4,206 people and is led by Gyo Sagara. In Q2 FY2027 it reported revenue of ¥116.26B and net income of ¥20.76B. The market values it at $7.21B.

2 · Latest results

What do the latest results show for Ono Pharmaceutical Co. (OPHLY)?

Short answer · as of

The most recent reported quarter, Q2 FY2027, carried revenue of ¥116.26B. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$737.15M Oct 29, 2026
Latest report · revenue estimate
$725.78M Oct 29, 2026
Latest report · revenue vs estimate
Above estimate Oct 29, 2026
Latest report · EPS vs estimate
Above estimate Oct 29, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 29, 2026$737.15M$725.78M$0.0934$0.0913
Jul 31, 2026$729.53M$685.03M$0.1076$0.0716
May 8, 2026$758.15M$717.88M$0.0037$0.0172
Feb 2, 2026$898.67M$833.28M$0.1315$0.0963
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2027¥116.26B¥20.76B¥14.69 (diluted)
Q1 FY2027¥117.69B¥24.47B¥17.76 (diluted)
Q4 FY2026¥120.93B¥833M¥0.58 (diluted)
Q3 FY2026¥142.43B¥29.38B¥20.85 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Ono Pharmaceutical Co. (OPHLY)?

Short answer · as of

The distress and quality screens read Altman Z 5.52 · Piotroski F 7. Trailing ratios: ROE 8.7% · ROA 6.8% · current ratio 3.32 · earnings yield 6.3% · free-cash-flow yield 10.7%.

4 · What to check next?

What should you watch next at Ono Pharmaceutical Co. (OPHLY)?

Short answer · as of

The next earnings report is expected on Feb 1, 2027.

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
0.0% Period end Sep 30, 2026
Previous quarter · ownership
0.0% Prior to period end Sep 30, 2026
Reporting holders
4 Period end Sep 30, 2026
Previous quarter · holders
6 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
First Command Advisory Services, INC.19,951
Rhumbline Advisers4,785
Westside Investment Management, INC.3,747
Calydon Capital2,604

Tracked investors

Which of the 16 named investors we follow held OPHLY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported OPHLY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Ono Pharmaceutical Co. (OPHLY)?

Read these with our analysis →

Common Questions About OPHLY (Healthcare)

These answers are editorial: 1 of these 8 answers is drawn from the OPHLY research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is OPHLY a good stock to buy?

Stock Expert AI does not rate OPHLY buy, sell or hold. Ono Pharmaceutical Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the OPHLY stock price today?

The last price recorded for Ono Pharmaceutical Co., Ltd. (OPHLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the unique considerations for investors in Ono Pharmaceutical Co., Ltd. given its ADR and OTC listing?

Investing in Ono Pharmaceutical Co., Ltd. through its OPHLY ADR on the OTC market presents several unique considerations. As a Level I ADR, it trades on the OTC Other tier, implying less stringent public disclosure requirements compared to major exchanges, which can make due diligence more challenging.

What are the key factors to evaluate for OPHLY?

Evaluate OPHLY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. As global populations age, the incidence of these diseases rises, creating a vast unmet medical need. Not financial advice.

How frequently does OPHLY data refresh on this page?

OPHLY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven OPHLY's recent stock price performance?

Ono Pharmaceutical Co., Ltd. (OPHLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across critical therapeutic areas like oncology, diabetes, and neurological disorders. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider OPHLY overvalued or undervalued right now?

The trailing P/E of Ono Pharmaceutical Co., Ltd. (OPHLY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research OPHLY before investing?

Before investing in Ono Pharmaceutical Co., Ltd. (OPHLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 49 figures on this page — 40 from Financial Modeling Prep (FMP), 4 with no recorded source, 4 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.